Name | Title | Contact Details |
---|---|---|
Ed Vertatschitsch |
Chief Operating Officer | Profile |
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Teleflex is a global provider of medical devices used in critical care and surgery. We serve healthcare providers with specialty devices for vascular access, general and regional anesthesia, urology, respiratory care, cardiac care and surgery.
Inogen`s mission to improve the quality of life of supplemental oxygen users began in 2001 when Mae, a beloved Grandmother, was prescribed oxygen therapy. Learn more about Mae`s Story here: http://www.inogen.com/about-inogen/meet-mae/. Inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. We estimate that more than 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy. Our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. We believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. With each step we take to improve our products and service, our customers take another step toward more freedom.
Seventh Sense Biosystems is a privately held medical technology company focused on developing innovative blood collection devices used in research and clinical testing. Our mission is to eliminate the barriers to successful blood sample collection and testing for health care professionals and consumers with simple, safe, mobile, and nearly painless technologies.
Invendo Medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology. Innovation activity in gastroenterological endoscopy has in the past decades nearly exclusively focused on the improvement of optical capabilities. However, invendo medical´s goal is to improve patient compliance and thereby increase the number of procedures performed. In order to achieve its goal the company first focussed on an application in the diagnosis and treatment of colorectal cancers (CRC). CRC is the second leading cause of cancer death with an estimated annual worldwide death toll of 510,000 people. More than 1 million new cases are diagnosed every year. However 90-100% of colorectal cancers can be avoided if diagnosed early on